141 related articles for article (PubMed ID: 37251313)
21. Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19.
Wai AK; Chan CY; Cheung AW; Wang K; Chan SC; Lee TT; Luk LY; Yip ET; Ho JW; Tsui OW; Cheung KW; Lee S; Tong CK; Yamamoto T; Rainer TH; Wong EL
Lancet Reg Health West Pac; 2023 Jan; 30():100602. PubMed ID: 36212676
[TBL] [Abstract][Full Text] [Related]
22. Nirmatrelvir plus ritonavir in COVID-19: a profile of its use.
Blair HA
Drugs Ther Perspect; 2023; 39(2):41-47. PubMed ID: 36532315
[TBL] [Abstract][Full Text] [Related]
23. A retrospective analysis of factors associated with the length of hospital stay in COVID-19 patients treated with Nirmatrelvir / Ritonavir.
Zheng J; Hong W; Zhou C; Hong D; Yan H; Shen Y
Front Pharmacol; 2023; 14():1146938. PubMed ID: 37342588
[No Abstract] [Full Text] [Related]
24. Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study.
Zhao X; Cheng Y; Zhang M; Qianda B; Zhouma B; Yangzhen B; Zheng Y; Zhang S; Zhao H
Infect Drug Resist; 2023; 16():6053-6060. PubMed ID: 37719651
[TBL] [Abstract][Full Text] [Related]
25. Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series.
Zhang AH; Diao ZL; Wang G; Guan YM; Liu YJ; Tian DL; Zhao YC; Huang HD; Liu WH
Diagn Microbiol Infect Dis; 2023 Nov; 107(3):115969. PubMed ID: 37677996
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS/MS in patients treated for COVID-19.
Martens-Lobenhoffer J; Böger CR; Kielstein J; Bode-Böger SM
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Dec; 1212():123510. PubMed ID: 36274268
[TBL] [Abstract][Full Text] [Related]
27. Pediatric Nirmatrelvir/Ritonavir Prescribing Patterns During the COVID-19 Pandemic.
Bose-Brill S; Hirabayashi K; Pajor NM; Rao S; Mejias A; Jhaveri R; Forrest CB; Bailey C; Christakis DA; Thacker D; Hanley PC; Patel PB; Cogen JD; Block JP; Prahalad P; Lorman V; Lee GM
medRxiv; 2022 Dec; ():. PubMed ID: 36597537
[TBL] [Abstract][Full Text] [Related]
28. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry.
Salmanton-García J; Marchesi F; Gomes da Silva M; Farina F; Dávila-Valls J; Bilgin YM; Glenthøj A; Falces-Romero I; Van Doesum J; Labrador J; Buquicchio C; El-Ashwah S; Petzer V; Van Praet J; Schönlein M; Dargenio M; Méndez GA; Meers S; Itri F; Giordano A; Pinczés LI; Espigado I; Stojanoski Z; López-García A; Prezioso L; Jaksic O; Vena A; Fracchiolla NS; González-López TJ; Colović N; Delia M; Weinbergerová B; Marchetti M; Marques de Almeida J; Finizio O; Besson C; Biernat MM; Valković T; Lahmer T; Cuccaro A; Ormazabal-Vélez I; Batinić J; Fernández N; De Jonge N; Tascini C; Anastasopoulou AN; Duléry R; Del Principe MI; Plantefeve G; Papa MV; Nucci M; Jiménez M; Aujayeb A; Hernández-Rivas JÁ; Merelli M; Cattaneo C; Blennow O; Nordlander A; Cabirta A; Varricchio G; Sacchi MV; Cordoba R; Arellano E; Gräfe SK; Wolf D; Emarah Z; Ammatuna E; Hersby DS; Martín-Pérez S; Nunes Rodrigues R; Rahimli L; Pagano L; Cornely OA;
EClinicalMedicine; 2023 Apr; 58():101939. PubMed ID: 37041967
[TBL] [Abstract][Full Text] [Related]
29. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
[TBL] [Abstract][Full Text] [Related]
30. Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study.
Gentile I; Scotto R; Schiano Moriello N; Pinchera B; Villari R; Trucillo E; Ametrano L; Fusco L; Castaldo G; Buonomo AR; Federico Ii Covid Team
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298596
[TBL] [Abstract][Full Text] [Related]
31. Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis.
Chan PLS; Singh RSP; Cox DS; Shi H; Damle B; Nicholas T
CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1897-1910. PubMed ID: 37803876
[TBL] [Abstract][Full Text] [Related]
32. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
Saravolatz LD; Depcinski S; Sharma M
Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
[TBL] [Abstract][Full Text] [Related]
33. Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?
Kim H; Yang JS; Ko JH; Lee M; Lee JY; Park S; Kim JW; Shin Y; Lee JM; Na YJ; Park BK; Kim H; Lee YH; Yang J; Huh K; Cho SY; Kang CI; Chung DR; Peck KR
Front Med (Lausanne); 2022; 9():988559. PubMed ID: 36314031
[TBL] [Abstract][Full Text] [Related]
34. Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study.
Luo W; Li KY; Dai C; Zhu W; Lin J; Lu F; Chen Q; Wang W; Zhuang Q; Lin Y
Infection; 2024 Apr; ():. PubMed ID: 38652225
[TBL] [Abstract][Full Text] [Related]
35. Short-Term Effectiveness of Oral Nirmatrelvir/Ritonavir Against the SARS-CoV-2 Omicron Variant and Culture-Positive Viral Shedding.
Lee E; Park S; Choi JP; Kim MK; Yang E; Ham SY; Lee S; Lee B; Yang JS; Park BK; Kim DS; Lee SY; Lee JY; Jang HC; Jeon J; Park SW
J Korean Med Sci; 2023 Feb; 38(8):e59. PubMed ID: 36852855
[TBL] [Abstract][Full Text] [Related]
36. Nirmatrelvir/Ritonavir Prescription Rate and Outcomes in Coronavirus Disease 2019: A Single Center Study.
Park JJ; Lee J; Seo YB; Na SH
Infect Chemother; 2022 Dec; 54(4):757-764. PubMed ID: 36450290
[TBL] [Abstract][Full Text] [Related]
37. Safety, efficacy, and pharmacokinetics of nirmatrelvir and ritonavir in patients with severe COVID-19 and renal impairment: A case report.
Zheng R; Fan X; Zhou F; Ye X; Sun J; Cheng J; Yuan Y; Wang Y; Cai X; Wei A
Heliyon; 2024 Mar; 10(6):e28069. PubMed ID: 38515712
[TBL] [Abstract][Full Text] [Related]
38. A case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis.
Tsuzawa A; Katada Y; Umemura K; Sugimoto M; Nishikawa A; Sato YK; Yoshida Y; Kitada N; Yonezawa A; Nakajima D; Date H; Terada T
J Pharm Health Care Sci; 2023 Apr; 9(1):12. PubMed ID: 37004119
[TBL] [Abstract][Full Text] [Related]
39. Management and Outcome of COVID-19 Infection Using Nirmatrelvir/Ritonavir in Kidney Transplant Patients.
Giguère P; Deschenes MJ; Loon MV; Hoar S; Fairhead T; Pazhekattu R; Knoll G; Karpinski J; Parikh N; McDougall J; McGuinty M; Hiremath S
Clin J Am Soc Nephrol; 2023 Apr; 18(7):913-9. PubMed ID: 37099447
[TBL] [Abstract][Full Text] [Related]
40. Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies.
Tang Y; Li Y; Song T
Front Immunol; 2023; 14():1150341. PubMed ID: 37081880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
